Open randomized non-inferiority controlled trial to examine the use of angiogenic factors (instead of feto-placental Doppler) for fetal growth restriction at term to reduce the rate of labor inductions, without worsening perinatal outcomes.
Pregnant women with estimated fetal weight (EFW) \< 10th centile between 36+0 and 37+6 weeks of gestation (WG) will receive complete ultrasonographic assessment consisting of feto-placental Doppler, amniotic fluid measurement and biophysical profile assessment. The cases not meeting any exclusion criteria will be offered to participate in this trial. After giving their informed consent a blood sample will be drawn in all of them and they will undergo randomization into two arms. 1. Intervention arm: In women allocated to the intervention group, the soluble fms-like tyrosine kinase/placental growth factor (sFlt-1/PlGF) result will be revealed to the investigators that will act according to the results of sFlt/PlGF: * Fetuses with sFlt-1/PlGF ≥38, elective delivery will be recommended at ≥37 weeks. * Fetuses with sFlt-1/PlGF \<38, weekly follow up will be recommended until delivery (at ≥40 weeks). 2. Control arm: In women allocated to the control group, the sFlt-1/PlGF result will be blinded to caregivers. Routine Doppler-based clinical care will be used to counsel women. Following the Doppler classification: * Fetuses with EFW below the 3rd centile or below the 10th centile accompanied by any impaired fetoplacental Doppler, elective delivery will be recommended at at ≥37 weeks. * Fetuses with EFW above the 3rd centile without any fetoplacental Doppler abnormality, elective delivery will be recommended at at ≥40 weeks. In both arms, fetuses will receive weekly follow-up from randomization to delivery consisting on feto-placental Doppler sFlt-1/PlGF and CTG. If any of the following is present at any time, earlier delivery will be recommended: * sFlt-1/PlGF ≥38 (only in the intervention group), * absent or reverse end-diastolic flow at the umbilical artery Doppler or DV PI\>95th centile * non-reassuring CTG * preeclampsia * diminished fetal movements * biophysical profile ≤ 6 or oligohydramnios (deepest pocket \<2 cm).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
1,088
In women allocated to the intervention group, the sFlt-1/PlGF result will be revealed to the investigators that will act according to the results of sFlt/PlGF: * Fetuses with sFlt-1/PlGF ≥38, elective delivery will be recommended immediately (within 24h) at ≥37 weeks. * Fetuses with sFlt-1/PlGF \<38 weekly follow up will be recommended and delivery at ≥40 weeks.
Hospital Universitario de A Coruña
A Coruña, Spain
Hospital General de Alicante
Alicante, Spain
Adverse perinatal outcomes
Cesarean delivery for non-reassuring fetal status or neonatal acidosis (artery cord potential of hydrogen (pH) \<7.15 + base excess \> -12 milliequivalent/L)
Time frame: 4-6 weeks
Rate of elective delivery
Percentage of women that required an elective delivery
Time frame: 4-6 weeks
Rate of Cesarean delivery
Percentage of women that required a Cesarean delivery
Time frame: 4-6 weeks
Rate of Induction of labor
Percentage of women that required an induction of labor
Time frame: 4-6 weeks
Rate of neonatal admission in intensive care unit
Percentage of newborns that required admission in intensive care
Time frame: 4-6 weeks
Time of neonatal admission in intensive care unit
Days in in intensive care of newborns that required admission
Time frame: 4-6 weeks
Rate of preeclampsia
Percentage of women that developed preeclampsia
Time frame: 4-6 weeks
Rate of neonatal complications
Percentage of newborns with adverse outcomes (composite)
Time frame: 4-10 weeks
Rate of maternal complications
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Hospital Germans Trias i Pujol
Badalona, Spain
Hospital Universitari Vall d'hebron
Barcelona, Spain
Hospital Universitario de Cabueñes
Cabueñes, Spain
Hospital Universitario Puerta del Mar
Cadiz, Spain
Hospital General Universitario de Elche
Elche, Spain
Hospital Universitario de Getafe
Getafe, Spain
Hospital Universitari Doctor Josep Trueta
Girona, Spain
Hospital Sant Joan de Deu de Manresa
Manresa, Spain
...and 10 more locations
Percentage of women with adverse outcomes (composite)
Time frame: 4-6 weeks
Rate of perinatal complications
Percentage of perinatal adverse outcomes (composite)
Time frame: 4-6 weeks
Rate of total deliveries at <37, <38, <39 and <40 weeks of gestation
Percentage of women that delivered at \<37, \<38, \<39 and \<40 weeks of gestation
Time frame: 4-6 weeks
Rate of elective deliveries at <37, <38, <39 and <40 weeks of gestation
Percentage of women that delivered electively at \<37, \<38, \<39 and \<40 weeks of gestation
Time frame: 4-6 weeks
Rate of newborns with birthweight <2000 and <2500 grams
Percentage of women that delivered a newborn with a birthweight \<2000 and \<2500 grams
Time frame: 4-6 weeks